Maintenance chemotherapy to help control advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies whether taking a combination of capecitabine and cyclophosphamide after your best prior treatment can help keep advanced breast cancer from growing. It may help people whose disease has already responded or is stable after “salvage” treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- Your cancer has been confirmed by pathology, and it is advanced (recurrent or metastatic) by scan or biopsy
- You have measurable disease you can track, or certain bone-only findings
- Your cancer is controlled after prior “salvage” treatment (complete response, partial response, or stable disease)
- You can likely tolerate treatment based on your general health (ECOG 0–2) and organ function
- You are not currently pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy combination (CMC) for people with early-stage, hormone receptor-positive, HER2-negative breast cancer who have a high risk of recurrence. It aims to understand if this oral regimen is effective and tolerable.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial tests a new approach to chemotherapy that adapts over time for people with advanced breast cancer that has not responded to first-line treatment. It is designed to personalize treatment based on how the cancer responds, potentially improving outcomes with fewer side effects.
This trial tests whether adjusting the dose of the oral chemotherapy capecitabine over time can control metastatic breast cancer that is estrogen-receptor positive (ER+) and HER2−. It is designed for patients who are starting capecitabine or have just started it, and the study will monitor blood changes and tumor response closely.
This trial tests a new drug combination (PCS6422 plus capecitabine) for people with advanced or metastatic breast cancer that has not responded to other treatments. The goal is to see if adding PCS6422 can make the chemotherapy work better.
This trial tests a drug called tetrathiomolybdate (TM) combined with capecitabine for people with triple-negative breast cancer who still have cancer cells after standard chemotherapy and surgery. The goal is to see if this combination can help prevent the cancer from coming back.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.